GnRH agonist administration after embryo transfer, in long protocol stimulated cycles, prevents ovarian hyperstimulation syndrome. A report of five cases.
BACKGROUND
Ovarian hyperstimulation syndrome (OHSS) is a frequent serious complication in controlled ovarian hyperstimulation for in vitro fertilization. Among the treatments for OHSS, the continuation of GnRH agonist during the luteal phase has been recently suggested.


METHODS
Five patients at risk for OHSS received 0.1 mg triptorelin for one week after embryo transfer in order to prevent OHSS.


RESULTS
All the five patients developed mild symptoms. None of them required hospitalization.


CONCLUSIONS
Although the pathophysiology of OHSS and the effects of GnRH agonist during the luteal phase remain unclear, the continuation of GnRH agonist seems to be a safe and effective treatment for OHSS.
Nikolettos
Nikos
N
Laboratory of Reproductive Physiology-IVF, Faculty of Medicine, Demokritus University of Thrace, Ktirio Proklinikon, Dragana, 68100 Alexandroupolis, Greece.
Asimakopoulos
Byron
B
Simopoulou
Mara
M
al-Hasani
Safaa
S
D000328:Adult; D004624:Embryo Transfer; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists; D006801:Humans; D008186:Luteolytic Agents / Q000008:administration & dosage*; D016471:Ovarian Hyperstimulation Syndrome / Q000188:drug therapy* / Q000517:prevention & control*; D011247:Pregnancy; D017329:Triptorelin Pamoate / Q000008:administration & dosage*
D008186:Luteolytic Agents; D017329:Triptorelin Pamoate; D007987:Gonadotropin-Releasing Hormone